Initial notification · 22.10.2026
Supply shortage Germany: Ipratropiumbromid 125 Mikrogramm / 1 ml Stulln – Initial notification, 22.10.2026 · ENR LE2026003894
Affected country: Germany · Reported period: 22.10.2026 – 01.04.2027 · Active ingredient: Ipratropiumbromid
Active ingredients
Notice context
A supply shortage has been recorded for Ipratropiumbromid 125 Mikrogramm / 1 ml Stulln in Germany. The stated reason is “Production problem”. The notice concerns the active ingredient Ipratropiumbromid and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Ipratropiumbromid 125 Mikrogramm / 1 ml Stulln is a supply signal concerning Ipratropiumbromid in Germany. The published reason “Production problem” determines which data should be verified first.
For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For manufacturing shortages, an agreed restart stock for Ipratropiumbromid 125 Mikrogramm / 1 ml Stulln can be received and distributed under control after release.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using PZN 11509801, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 22.10.2026 to 01.04.2027 with the primary source and potential suppliers.
- Prioritise hospital demand, supply relevance and the escalation route with the accountable market participants.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Ipratropiumbromid 125 Mikrogramm / 1 ml Stulln: